You are here

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
University of Alabama at Birmingham/Children's of Alabama
Birmingham, Alabama, 35233 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
CD33 Positive Acute Myelogenous Leukemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
3+ months
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Confirmed diagnosis of relapsed/refractory AML (defined as >=5% marrow blasts by
morphology), including MDS, with persisting rising blasts and no other comparable or
satisfactory alternative therapy available. If bone marrow has morphology but the patient has evidence of relapse with extra-medullary disease
progression. In select cases presenting with conversion of MRD from negative to
positive, treatment with GO may be allowed where no alternative treatments are
feasible.

OR

- Confirmed diagnosis of relapsed or refractory APL with persisting or rising leukemic
burden (either by morphology, cytogenetic analysis or by molecular techniques), and no
other comparable or satisfactory alternative therapy available.

- Documentation that malignant cells express CD33

4) Age >=3 months

5) Adequate non-hematologic organ function

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Untreated AML and MDS or AML and MDS in complete remission.

- Patients with a known history of VOD/SOS.

- Patients with a known hypersensitivity to Mylotarg or its parts: hP67.6 antibody,
calicheamicin derivatives or other ingredients.

- Participation in other studies involving investigational drug(s) (Phases 1-4) during
study participation.

NCT02312037
Pfizer
Available
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Myelodysplastic Syndrome, Acute Myeloid Leukemia
NCT02367456
All Genders
18+
Years
Multiple Sites
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
NCT01970865
All Genders
18+
Years
Multiple Sites
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

An expanded access/compassionate use protocol that allows access to Mylotarg for relapsed/refractory AML CD33 positive patients in the USA.

Contact: [email protected]

Contact:

[email protected]

Expanded Access
Biological: Antibody Drug Conjugate Chemotherapeutic

Three Treatment Regimens:

  1. Mylotarg <=9 mg/m2 as a single agent on Day 1 & 14 of a 28-day cycle for a total of two cycles
  2. Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen
  3. Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL
Other Name: Gemtuzumab ozogamicin
Not Provided
 
Available

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Contact: Mylotarg Expanded Access Team [email protected]
Spain,   United States
 
 
NCT02312037
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now